Background: Venous thromboembolism (VTE) may be the earliest sign of cancer. Risk factors associated with the presence of an occult cancer in patients with a first acute unprovoked VTE are unknown. We sought to assess the risk factors predictive of occult cancer detection in patients with a first unprovoked symptomatic VTE.

Methods:Post-hoc, pre-defined analyses of the multicenter open-label randomized controlled trial - Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) trial (Carrier M et al. N Engl J Med 2015). The trial compared comprehensive computed tomography (cCT) of the abdomen and pelvis in addition to limited occult-cancer screening (complete history and examination, basic laboratory testing, chest radiography, and breast, cervical and prostate cancer screening) with limited occult-cancer screening alone in patients with a first unprovoked episode of VTE. Cox proportional hazard models were used to analyze the effect of specific risk factors on the outcome of occult cancer within 12 months of a diagnosis of unprovoked VTE. Multivariable analysis was performed using Cox proportional hazard models that included all variables that achieved a p value of < 0.20 in univariate analyses.

Results: A total of 854 patients were randomized to limited occult cancer screening only, or limited occult cancer screening in combination with a cCT. The mean age was 54 years and 67.4% were males. A total of 33 (3.9%; 95% C.I. 2.8-5.4) patients received a new diagnosis of cancer at 12 months follow-up. Age ≥ 60 years, compared to age < 60 years, was a predictor of cancer with a corresponding hazard ratio (HR) of 2.90 (95% C.I. 1.44-5.83, p=0.003). A previous provoked VTE in patients was also associated with a higher risk of developing cancer (HR=3.57, 95% C.I. 1.38-9.25, p=0.009). Patients with an unprovoked deep vein thrombosis (DVT), compared to either those with a pulmonary embolism (PE) only or both DVT and PE, seemed more likely to have a diagnosis of cancer. However, this trend was not statistically significant. (Table 1) These results were confirmed on multivariable analysis. Patients exhibiting one of these characteristics had a three-fold higher risk of occult cancer compared with patients without these characteristics. (Table 1)

Conclusion: Age at unprovoked VTE diagnosis (≥ 60 years) and prior provoked VTE are predictors of occult cancer, and could potentially be used to identify a group of patients with unprovoked VTE at high risk of underlying cancer.

Table 1.

Risk factors of occult malignancy among patients with a first unprovoked symptomatic VTE.

Patients without cancer (%)
(n = 821)
Patients with cancer (%)
(n = 33)
Univariate analysis
Hazard Ratio (95% C.I.)
P valueMultivariable analysis
Hazard Ratio (95% C.I.)
P value
Age at diagnosis ≥ 60 years 288 (35.1) 20 (60.6) 2.90 (1.44-5.83) 0.003 3.0 (1.47-5.99) 0.002 
Male sex 555 (67.6) 21 (63.6) 0.72 (0.35-1.46) 0.358 
Prior provoked VTE 42 (5.1) 5 (15.2) 3.57 (1.38-9.25) 0.009 3.8 (1.46-10.03) 0.006 
Type of current VTE       
DVT only 444 (54.3) 24 (72.7) 1.91 (0.89-4.12) 0.097 2.1 (0.97-4.51) 0.061 
PE only 271 (33.1) 7 (21.2) 0.60 (0.26-1.38) 0.229 
DVT + PE 103 (12.6) 2 (6.1) 0.54 (0.13-2.24) 0.392 
Baseline medications       
Oral contraceptive pill 48 (5.8) 0 (0.0) 
Exogenous estrogen 18 (2.2) 1 (3.0) 1.51 (0.21-11.07) 0.685 
Antiplatelet agent 39 (4.8) 1 (3.0) 0.62 (0.09-4.56) 0.641 
Oral anticoagulant 688 (83.8) 26 (78.8) 0.66 (0.29-1.53) 0.337 
LMWH 391 (47.7) 15 (45.5) 0.68 (0.34-1.36) 0.275 
Patients without cancer (%)
(n = 821)
Patients with cancer (%)
(n = 33)
Univariate analysis
Hazard Ratio (95% C.I.)
P valueMultivariable analysis
Hazard Ratio (95% C.I.)
P value
Age at diagnosis ≥ 60 years 288 (35.1) 20 (60.6) 2.90 (1.44-5.83) 0.003 3.0 (1.47-5.99) 0.002 
Male sex 555 (67.6) 21 (63.6) 0.72 (0.35-1.46) 0.358 
Prior provoked VTE 42 (5.1) 5 (15.2) 3.57 (1.38-9.25) 0.009 3.8 (1.46-10.03) 0.006 
Type of current VTE       
DVT only 444 (54.3) 24 (72.7) 1.91 (0.89-4.12) 0.097 2.1 (0.97-4.51) 0.061 
PE only 271 (33.1) 7 (21.2) 0.60 (0.26-1.38) 0.229 
DVT + PE 103 (12.6) 2 (6.1) 0.54 (0.13-2.24) 0.392 
Baseline medications       
Oral contraceptive pill 48 (5.8) 0 (0.0) 
Exogenous estrogen 18 (2.2) 1 (3.0) 1.51 (0.21-11.07) 0.685 
Antiplatelet agent 39 (4.8) 1 (3.0) 0.62 (0.09-4.56) 0.641 
Oral anticoagulant 688 (83.8) 26 (78.8) 0.66 (0.29-1.53) 0.337 
LMWH 391 (47.7) 15 (45.5) 0.68 (0.34-1.36) 0.275 

VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; LMWH, low molecular weight heparin

Disclosures

Lazo-Langner:Pfizer: Honoraria, Other: Participated in studies funded by this organization, Speakers Bureau; LEO Pharma: Honoraria, Other: Participated in studies funded by this organization; Boehringer Ingelheim: Honoraria, Other: Participated in studies funded by this organization; Bayer: Honoraria, Other: Participated in studies funded by this organization; Daiichi-Sankyo: Other: Participated in studies funded by this organization; Novartis: Other: Participated in studies funded by this organization; Celgene: Other: Participated in studies funded by this organization; Alexion: Research Funding. Shivakumar:Bayer: Honoraria. Routhier:Sanofi-Aventis: Research Funding. Douketis:Janssen: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria; Pfizer: Honoraria; Sanofi-Aventis: Honoraria; Daiichi-Sankyo: Consultancy; Actelion: Consultancy; Biotie: Other: Advisory board; The Medicines Company: Other: Advisory board; Bayer: Consultancy; Boehringer Ingelheim: Consultancy, Honoraria. Carrier:LEO Pharma: Consultancy, Research Funding; BMS: Research Funding; Bayer: Consultancy; Pfizer: Consultancy.

Author notes

*

Asterisk with author names denotes non-ASH members.

This icon denotes a clinically relevant abstract

Sign in via your Institution